{
  "id": 12842255,
  "title": "I spent 3 days with pharma executives. They're suddenly taking longevity seriously.",
  "url": "https://urgent.news/2026/10/08/i-spent-3-days-with-pharma-executives-theyre-suddenly-taking",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T10:09:01.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/why-big-pharma-betting-longevity-drugs-2026-10"
  },
  "original_language": "en",
  "account": "Pharma leaders, scientists, and visionaries all agree: this annual gathering is the most important event to attend in the field of longevity. The annual shindig took place in Boston last weekend, with the FDA joining the conversation for the first time. Longevity is no longer a taboo word in the pharmaceutical world; it's now seen as an investment opportunity. For a long time, longevity was avoided by serious drugmakers, who associated it with supplement gurus, Silicon Valley biohackers, and anti-aging fraudsters. However, that perception changed after the 2026 Aging Research and Drug Discovery (ARDD) meeting, which was held in Boston, the epicenter of US biotech industry. US regulators, executives from major drugmakers, and longevity pioneers gathered for three days to discuss how drugs to combat age-related decline could become a reality sooner rather than later.\n\nExecutives from prominent drugmakers like Pfizer, GSK, AstraZeneca, Novartis, and Eli Lilly enthusiastically discussed their plans for longevity drugs. Eli Lilly's associate vice president of healthy aging, Thomas Marron, remarked that they see the space as important because that's where patients will be. There was a palpable excitement in the air, with researchers expressing amazement at the possibility of a future longevity pill, while struggling to formulate actual therapies.\n\nThe attendees at ARDD represented a diverse mix of drugmakers, scientists, doctors, founders, and investors. The pharmaceutical presence has been growing, with Eli Lilly and Novo Nordisk being two of the most notable participants. The shift in attitude towards aging has been remarkable. Just a few years ago, scientists debated whether aging should be considered a disease, lamenting the lack of an FDA approval pathway. Now, they are actively building frameworks and discussing data that the FDA will need to review to assess the efficacy of longevity drugs.",
  "summary": "Inside the conference where FDA officials, Eli Lilly, Pfizer, and biotech leaders mapped out the future of longevity medicine.",
  "key_points": [
    "Pharma leaders gather in Boston for ARDD meeting",
    "FDA joins conversation for first time",
    "Executives from Pfizer, GSK, AstraZeneca, Novartis, Eli Lilly discuss longevity drugs"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}